Detalhe da pesquisa
1.
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline.
Br J Haematol
; 204(3): 784-804, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38247114
2.
Capture-based targeted sequencing using a T-cell control in myeloid malignancies and idiopathic cytopenias.
Br J Haematol
; 204(4): 1325-1334, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38462984
3.
Retinoic acid-responsive CD8 effector T cells are selectively increased in IL-23-rich tissue in gastrointestinal GVHD.
Blood
; 137(5): 702-717, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32905596
4.
Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
Blood
; 135(9): 680-688, 2020 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31932839
5.
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive).
Haematologica
; 106(10): 2694-2706, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33910333
6.
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.
Blood
; 131(3): 301-310, 2018 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29150421
7.
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
Blood
; 132(20): 2154-2165, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181174
8.
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Br J Haematol
; 185(3): 450-467, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30729512
9.
Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
Br J Haematol
; 180(3): 346-355, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29076145
10.
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.
Br J Haematol
; 196(4): e33-e37, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636043
11.
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
N Engl J Med
; 371(10): 906-17, 2014 Sep 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-25184863
12.
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.
Blood
; 125(25): 3878-85, 2015 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25833957
13.
Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.
Blood
; 125(26): 4060-8, 2015 Jun 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-25896651
14.
Disease evolution and outcomes in familial AML with germline CEBPA mutations.
Blood
; 126(10): 1214-23, 2015 Sep 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26162409
15.
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial.
Biol Blood Marrow Transplant
; 22(6): 1009-1016, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26827659
16.
Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high-risk myeloma patients - a single centre experience.
Br J Haematol
; 193(2): 420-423, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33713421
17.
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
Br J Haematol
; 193(3): e19-e22, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33715154
18.
Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial.
Haematologica
; 101(6): 724-31, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26921360
19.
Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation.
Proc Natl Acad Sci U S A
; 110(33): 13576-81, 2013 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-23901108
20.
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
Br J Haematol
; 170(3): 336-48, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25891006